



## Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference

February 28, 2024

BRISBANE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced that the Company's management team will participate in the 44th Annual TD Cowen Health Care Conference, which is taking place from March 4<sup>th</sup> to 6<sup>th</sup> at the Marriott Copley Place in Boston, MA.

### **IgAN Corporate Panel Discussion Details:**

Date: Monday, March 4<sup>th</sup>  
Time: 9:10 AM ET  
Vera Rep.: Robert Brenner, M.D., Chief Medical Officer

### **Vera Therapeutics Fireside Chat Details:**

Date: Monday, March 4<sup>th</sup>  
Time: 2:10 PM ET  
Presenter: Marshall Fordyce, M.D., Chief Executive Officer  
Webcast: <https://wsw.com/webcast/cowen154/vera/2016052>

A replay of the event will be available for 90 days and can be accessed by visiting the "[Investor Calendar](#)" section of the Vera Therapeutics website.

The management team will also participate in one-on-one investor meetings.

### **About Vera Therapeutics**

Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera's mission is to advance treatments that target the source of immunologic diseases in order to change the standard of care for patients. Vera's lead product candidate is atacept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A Proliferation-Inducing Ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger's disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacept and MAU868. For more information, please visit [www.veratx.com](http://www.veratx.com).

For more information, please contact:

### **Investor Contact:**

Joyce Allaire  
LifeSci Advisors  
212-915-2569  
[jallaire@lifesciadvisors.com](mailto:jallaire@lifesciadvisors.com)

### **Media Contact:**

Mari Purpura  
LifeSci Advisors  
[mpurpura@lifesciadvisors.com](mailto:mpurpura@lifesciadvisors.com)